Health Canada Approves Moderna's mRNA RSV Vaccine mRESVIA
核心洞察
Health Canada has approved Moderna's mRESVIA, the first mRNA vaccine for respiratory syncytial virus (搜索) (RSV) in Canada, targeting adults aged 60 and over.
The approval was based on the Phase III ConquerRSV trial, which demonstrated an 83.7% efficacy in preventing RSV-related lower respiratory tract disease (LRTD).
mRESVIA is unique as a single-dose, prefilled syringe, streamlining administration and reducing potential errors for healthcare professionals.
Moderna's mRESVIA, a messenger ribonucleic acid (mRNA) vaccine designed to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (搜索) (RSV), has received approval from Health Canada for use in individuals aged 60 and over. This marks the first mRNA RSV vaccine available in Canada and Moderna's second product approved in the country. The approval is based on data from the Phase III ConquerRSV trial, which enrolled approximately 37,000 participants across 22 countries.
Efficacy and Clinical Trial Data
The ConquerRSV Phase III trial demonstrated a significant efficacy rate of 83.7% in preventing RSV-related LRTD after a median follow-up of 3.7 months. This data underscores the potential of mRESVIA to reduce the burden of RSV in older adults, who are particularly vulnerable to severe outcomes from the infection.
Stéphane Bancel, Moderna CEO, stated, "Today’s approval is an example of how our mRNA platform can help address significant public health challenges like RSV. As our second product approved by Health Canada, mRESVIA underscores our commitment to leveraging mRNA technology to protect vulnerable populations and contribute to a healthier future for Canadians."
Unique Formulation and Availability
mRESVIA is currently the only available RSV vaccine in a single-dose, prefilled syringe format. This design aims to simplify the vaccination process for healthcare providers, potentially minimizing errors and saving time. The vaccine is anticipated to be available in Canada in early 2025.
Global Regulatory Landscape
Health Canada's approval follows similar authorizations granted in Europe, Qatar, and the United States. The US Food and Drug Administration (FDA) approved mRESVIA in June, with availability expected in time for the 2024-25 respiratory virus season.
Vaccination Recommendations
Canada’s National Advisory Committee on Immunization recommends RSV vaccination for adults aged 75 and over, as well as those 60 years and older residing in chronic care facilities and nursing homes. For community-dwelling individuals over 60, vaccination decisions should be made in consultation with a healthcare provider.
Mechanism of Action
The mRESVIA vaccine contains an mRNA sequence encoding the RSV F glycoprotein (搜索), which is crucial for the virus's ability to infect host cells. By eliciting an immune response against this protein, the vaccine aims to prevent RSV infection and subsequent LRTD.